Assembled for our collective experience and passion for cell therapy
Dedicated to quality and driven by excellence, we are committed to improving the lives of patients worldwide. We are steadfast in our goal to develop innovative cellular therapies that bring us closer to a cure.
From the very beginning, we’ve been focused on science. We came together
as a team of experts dedicated to quality, driven by excellence, and committed
to experimentation. Though we faced many challenges, we remain fearless in
our research and rigorous in our thinking, pushing ourselves to work harder.
At Legend Biotech, we have the opportunity to change the way treatments are developed
across diseases and continents. Our goal is to reinvigorate
treatment approaches in oncology and beyond.
The spark of hope is lit
and we’re using that hope to ignite the future of cell therapy!
We welcome the opportunity to reinvigorate the treatment approaches in oncology and the future of cell therapy.
Today, our research is focused on continuous innovation in the field of cell therapy.
We are also future-focused on emerging technologies that can help address
some of the most chronic and life-threatening diseases.
Our goal is to reimagine healthcare and to deliver transformative
treatments.
And at Legend Biotech, that’s what we’re doing every day.
Our driving force at Legend Biotech is sharing our passion for developing cutting-edge cell therapies with our colleagues and the healthcare community. We do that by being:
Efficient: We constantly look for inspiration inside
and outside the world of cell therapy.
Transparent: We work openly and collaboratively to establish
trust and protect the relationships we’ve developed over time.
Passionate: We have an innate drive for scientific
advancement in order to bring the power of cell therapies to patients.
Fearless: We focus on the importance of continuous learning
and intellectual humility, using these attributes to advance to the next step.
Accountable: Be reliable and dependable; do what
you say you will do. This idea is at the core of what we believe.
Dr Xu has been the Chief Executive Officer since February, 2018.
Before joining Legend Biotech, Dr Xu was Senior Vice President at
Merck where she led teams in biologics and vaccines discovery,
development, and commercialization. Prior to Merck, Dr Xu held
positions at Gilead, Novartis, Amgen, Chiron, GlaxoSmithKline,
and Genentech.
With more than 25 years of biologic, biosimilar, vaccine and cell
therapy discovery, development, commercialization, and
life-cycle-management experience, Dr Xu has contributed to the
successful commercial launch of nearly 25 products.
Dr Xu received her Bachelor of Science in biochemistry from Nanjing
University, China, her Doctor of Philosophy in biochemistry from
the University of Maryland at College Park in College Park,
Maryland, USA, and completed her post-degree training in virology
and gene therapy at the University of California, San Diego in
San Diego, California, USA.
Dr Fan is a co-founder of Legend Biotech and its Chief Scientific Officer
since 2014. Dr Fan has been published in numerous peer-reviewed academic
journals, including a major revision in the clinical guidelines of pediatric
organ transplantation published in Nature Medicine. Dr Fan was also awarded
a “New Key Opinion Leader” award by The International Society of Transplantation.
Dr Fan earned his Doctor of Medicine degree at Xi’an Jiaotong University, China,
and completed his surgical residency at the Jiaotong University Kidney Transplant
Center, China. Dr Fan later obtained his Doctor of Philosophy in applied immunology at
Hiroshima University, Japan, and completed postdoctoral training in the field of
human B-cell tolerance at the Hospital for Sick Children at the University
of Toronto, Canada.
Dr Huang has served as Chief Financial Officer since July, 2019. He brings over
9 years of experience in research and development at major multi-national pharmaceutical
companies and 12 years of experience as a biotechnology analyst on Wall Street.
Most recently, Dr Huang was a Managing Director and Head of Biotech Equity Research
at Bank of America Merrill Lynch where he led a team of analysts covering more than
30 biotechnology companies including Amgen, Gilead, Celgene, Biogen and others that
encompass a wide range of therapeutic areas. His knowledge and expertise have been
recognized by the Institutional Investor survey as a top ranked biotechnology analyst
on Wall Street. Dr Huang has been a biotech analyst since 2007 and previously worked
at Wells Fargo (formerly Wachovia), Credit Suisse, Gleacher and Barclays before joining
Bank of America Merrill Lynch. Besides providing investment research to investors,
Dr. Huang and his team conducted due diligence for numerous successful initial public
offerings (IPOs) and follow-on offerings in the biotechnology sector.
Prior to his Wall Street career, Dr Huang was a Principal Scientist at Schering-Plough
(now Merck & Co.) in the Department of Chemical Research focusing on small molecule drug
discovery in the therapeutic areas of cardiovascular and central nervous system. He is the
co-author of multiple patents and peer reviewed publications. Dr Huang received his Doctor
of Philosophy in Bio-organic Chemistry from Columbia University, New York, USA. He also
studied in the Special Class for the Gifted Young at the University of Science and Technology
of China and Columbia Business School.
Dr Meeta Chatterjee has served as the Senior Vice President of
Global Business Development since March, 2019. She was previously
Head of Strategy, Transactions, and Operations within the Business
Development and Licensing (BD&L) group at Merck Research Labs. Dr
Chatterjee oversaw discovery and late-stage transactions worldwide,
as well as early-stage transactions in key geographies. She also was
responsible for Merck’s BD&L governance, oversight, and control as
well as out-licensing efforts.
Dr Chatterjee has over 30 years of broad strategic and operational
experience in pharmaceutical research and development, mergers and
acquisition evaluation, in-licensing, and externalization activities.
Over the course of her extensive career, she has led/contributed to
>150 transactions/collaborations with a cumulative financial value of
~$1 billion USD. She has led research efforts in the areas of hypertension,
atherosclerosis, and obesity, and was an integral contributor to the
discovery of ZETIA and ZONTIVITY.
Dr Chatterjee received her undergraduate education at St. Xavier’s University
in Ahmedabad, India, and Rutgers University (B.A., Hons Physics), New Jersey,
USA. She received her Doctor of Philosophy in Physiology from Rutgers University
and completed a postdoctoral fellowship in the Department of Physiology at the
University of Virginia, School of Medicine, Virginia, USA. Dr Chatterjee is
also active in industry and licensing focused organizations.
Dr Syed Rizvi has served as Vice President of Clinical Development
and Medical Affairs since June, 2018. He also oversees data sciences
and product safety functions. Dr Rizvi brings more than 20 years of
successful oncology drug development experience and has been responsible
for setting the medical/clinical strategy for clinical development
resulting in new indications and potential label expansion. He has
demonstrated a consistent track record of solid performance and
clinical expertise by taking drugs successfully to health authority
approvals and subsequent drug launches.
Dr Rizvi joined Legend Biotech from Celgene Corporation, where he was
the head of the CAR-T program in Global Medical Affairs and also
served as head of Hematology for US Medical Affairs. At Celgene,
he was responsible for the strategic direction and management of
the CAR-T and immuno-oncology therapy portfolios, built a comprehensive
clinical research alliance, and developed an immuno-oncology network
with researchers to harness scientific discovery for targeted patient
outcomes. Prior to Celgene, Dr Rizvi held global clinical leadership
roles in oncology programs at Novartis Oncology and Merck.
Dr Rizvi received his Doctor of Medicine degree from Dow University
of Health Sciences, Pakistan, and spent several years in direct
patient care.
Dr Tracy Luo has served as Vice President of Clinical Development,
Greater China, since May, 2018. Dr Luo has a comprehensive understanding
of the Chinese regulatory environment and dynamics and has more than 15
years of experience advancing clinical development programs in the oncology
and hematology therapeutic areas. Previously, Dr Luo led multiple
global oncology and hematology products through the clinical development
stage at AstraZeneca, Amgen, and Sanofi. Her efforts led to numerous
successful regulatory filings and commercial launches, including IRESSA,
FASLODEX, BLINCYTO, KYPROLIS, and ELOXATIN. Previously, Dr Luo spent more
than 6 years as a pharmacology research scientist at Fudan University
Shanghai Medical School, China.
Dr Luo earned her Doctor of Medicine degree from Qingdao Medical
College, China, and a Master of Science degree in pharmacology
at Fudan University, China.
Mr Steve Gavel has served as Vice President of Commercial Development
since July, 2018. He brings over 28 years of commercial
experience in biotech start-ups, leading pharmaceutical and medical device organizations.
Most recently, Mr Gavel worked at Celgene Corporation, where he led US CAR-T
commercial development activities for their bb2121 program. In
this role, he led commercial launch strategy and execution planning
in the United States. Prior to Celgene, Mr Gavel led VELCADE marketing strategy
and execution at Takeda Oncology, where he served as Senior Marketing Director.
Prior to Takeda Oncology, Mr Gavel held multiple sales, marketing
and market access leadership positions in companies such as Syntex,
Immunex, Johnson & Johnson, and IMS Health.
Mr Gavel earned his Bachelor of Science degree in finance and business
administration from Millersville University in Millersville, Pennsylvania, USA.
Dr Chong Yang has served as Vice President of Commercial Development,
Greater China since July, 2018. Formerly, Dr Yang held various sales
and marketing leadership roles with increasing responsibilities in
multinational pharmaceutical companies including Roche Oncology,
Bayer Oncology, and Novartis Oncology. He brings more than 17 years
of commercial experience and has extensive expertise in promoting
and launching products including GLIVEC, NEXAVAR, AVASTIN, and
RITUXAN in the China market.
Dr Yang earned his Master of Medicine degree from Nanjing University,
China, and served as a Surgical Resident at Zhongda Hospital at Southeast
University, China.
Ms Liz Gosen has served as Senior Vice President of Technical
Operations since May, 2019. Prior to joining Legend Biotech,
she was Vice President of Biologics Operations at Eli Lilly
where she was responsible for the manufacturing, warehouse,
and supply chain organizations for a 2-suite multi-product
commercial and clinical monoclonal antibody (mAb) manufacturing facility.
During her 25-year career she has developed a broad experience
in biotechnology manufacturing operations through assignments
in the following areas: multiple large-scale manufacturing facility
capital design/builds and start-ups, process engineering support
and management, facility and utilities management, site process
technology transfers, and successful process validation as
well as operations, logistics, and validation management.
Ms Gosen has international commercial scale manufacturing experience as
a Business Unit Leader of an Eli Lilly large-scale mAb facility in Ireland.
She was responsible for the organizational build and development of
the operations organization from the commissioning and qualification
support phase through to FDA approval and commercial operations. Ms Gosen
has extensive global regulatory inspection experience and has been directly
involved in the worldwide regulatory submission, pre-approval inspection,
and launch of five biologics products.
Ms Gosen holds a Bachelor of Science Degree in Materials Science & Engineering
with a minor in Biology from Lehigh University, Pennsylvania, USA, and an
MBA of Finance from Seton Hall University, New Jersey, USA.
Dr David He has served as Vice President of Technical Operations
(previously Vice President of Manufacturing) since May, 2018.
Previously, he was the Head of Clinical Science & Technology at
Boehringer Ingelheim, leading the Good Manufacturing Practice (GMP)
Clinical Manufacturing and Manufacturing Science and Technology/Tech
transfer teams. Dr He has held research and manufacturing positions
of increasing responsibilities in large US pharmaceutical companies
and has more than 25 years of experience working in both industry
and academic settings with expertise in the fields of biologics
development, chemistry, manufacturing and control (CMC) process
development, and cGMP manufacturing. Dr He has developed a number
of successful manufacturing processes for biologics, which have led
to cFDA/FDA/EMA approval. He has extensive cross-functional
leadership and hands-on experience in CMC process development and
manufacturing (from lab scale through pilot scale to large-scale
cGMP manufacturing), as well as a depth of experience in tumor
cell biology, tumor immune cell therapy, and molecular biology.
Dr He completed his postdoctoral training in immunology from the
University of Alabama at Birmingham in Birmingham, Alabama, USA.
He received his Doctor of Philosophy degree in molecular biology
from Sun Yat-sen University, China; a Master of Science degree in
oncology (tumor cell biology and immunology) from Guangzhou Medical
University, China; and a Doctor of Medicine degree from Hengyang
Medical College, China.
Mr Alan Kick has served as Vice President of Global Quality since
August, 2018. Prior to joining Legend Biotech, Mr Kick was Executive
Director of Quality Operations at Celgene Corporation, responsible
for the Global External Quality, Cell Therapy Quality, and Global
Quality Supply Chain organizations. He previously held positions of
increasing responsibility at Dendreon, Wyeth, Johnson & Johnson,
and Hoffmann-La Roche. Mr Kick has nearly 30 years of experience
in the pharmaceutical industry, including solid oral dosage,
semi-solids, biologics, vaccines, sterile lyophilized products,
cellular therapies, active pharmaceutical ingredient (API),
commercialization, development, and laboratory management.
Mr Kick received a Bachelor of Science degree in biology from The
College of New Jersey in Ewing, New Jersey, USA, and a Master of
Science degree in business management from New Jersey Institute
of Technology in Newark, New Jersey, USA.
Dr Yuhong Qiu has served as Vice President of Global Regulatory
Affairs since May, 2018. Previously, Dr Qiu served as Executive
Director of Regulatory Affairs at Novartis Oncology, where she
worked for 12 years with increasing responsibilities. She has
broad regulatory expertise spanning across both small and large
molecule (biologics) development. Dr Qiu has led numerous successful
global regulatory filings from first-to-human studies to marketing
authorization applications. Before joining Novartis Oncology, Dr Qiu
worked for 8 years at Johnson & Johnson, where she led a team of
scientists in drug discovery and gained rich experience in drug
candidate selection and characterization and preparation of nonclinical
documents for first-in-human studies.
Dr Qiu received her Doctor of Philosophy degree and completed her
postdoctoral training from the Baylor College of Medicine in Houston,
Texas, USA. She received her Bachelor of Science degree in biochemistry
from Wuhan University, China. Dr Qiu has authored or co-authored more
than 30 publications in peer-reviewed journals.
Mr Shu (Simon) Wu has served as Vice President of Operations, Research
& Development Institute II, since October, 2017. Formerly, Mr Wu was the
Vice President of Operations for the Discovery Biology Business Unit at
GenScript Inc., leading antibody therapeutics discovery and operations
activities. Mr Wu is the co-inventor of 15 patents in the field of
immunotherapy and has more than 10 years of therapeutic antibody discovery
and development, organizational capability building, and management
experience. He has contributed to the development of successful novel
discovery platforms and has led many antibody and chimeric antigen
receptor T-cell (CAR-T) candidates into clinical development.
Mr Wu received his Master of Science degree in molecular biology from
the Chinese Academy of Science, China, and a Bachelor of Arts degree
in microbiology from Nanjing Agriculture University, China.
For the past 16 years, Dr Zhang has been the Chairman and Chief Executive Officer of GenScript Inc., the world’s largest gene synthesis corporation. In 2014, Dr Zhang founded Legend Biotech under GenScript Inc., expanding the corporation’s business goal to research, manufacture, and commercialize a broad range of immunotherapy treatments. In 2018, Legend Biotech became the first Chinese CAR-T company to receive Investigational New Drug approval in both China and the United States. That same year, Dr Zhang was awarded Person of the Year at the China Healthcare Summit in recognition of his contribution to and significant impact on the healthcare field.
Before founding GenScript Inc., Dr Zhang worked as a Principal Scientist at Schering-Plough from 1995 to 2002 where he received its Presidential Award. Dr Zhang received his PhD in biochemistry from Duke University in Durham, North Carolina, USA; and his Master’s degree from Nanjing University, China. Dr Zhang has authored more than 20 articles published in peer-reviewed journals and is owner of 9 scientific patents.
Dr Xu has been the Chief Executive Officer since February, 2018.
Before joining Legend Biotech, Dr Xu was Senior Vice President at
Merck where she led teams in biologics and vaccines discovery,
development, and commercialization. Prior to Merck, Dr Xu held
positions at Gilead, Novartis, Amgen, Chiron, GlaxoSmithKline,
and Genentech.
With more than 25 years of biologic, biosimilar, vaccine and cell
therapy discovery, development, commercialization, and
life-cycle-management experience, Dr Xu has contributed to the
successful commercial launch of nearly 25 products.
Dr Xu received her Bachelor of Science in biochemistry from Nanjing
University, China; her Doctor of Philosophy in biochemistry from
the University of Maryland at College Park in College Park,
Maryland, USA; and completed her post-degree training in virology
and gene therapy at the University of California, San Diego in
San Diego, California, USA.
Ms Wang is the President of GenScript Inc. and a board member for Legend Biotech Corporation, responsible for the companies’ strategies and overall operational management. Prior to joining the organization, she worked as an Environmental Monitoring Engineer at Shenzhen Futian Environment Protection Surveillance Station for nearly a decade.
Ms Wang holds several advanced degrees, including a Master of Science degree from Wuhan University, China, in August 1993; a Master’s degree in Computer Sciences from Bridgeport University in Bridgeport, Connecticut, USA; and an Executive Master of Business Administration degree from the China Europe International Business School, China.
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.
*LCAR-B38M identifies the investigational product being studied in China and Janssen Biotech, Inc.'s JNJ-68284528 (also referenced as JNJ-4528) identifies the investigational product being studied in the United States, both of which are representative of the same CAR-T cell therapy.
You are about to leave LegendBiotech.com.
Are you sure you want to leave so soon?
By continuing to use our site, you agree to terms on our Legal Notice.
You can learn more about how we use cookies by viewing our Legal Notice.